ClinicalTrials.gg
CompletedNCT02142634Updated Jul 22, 2020

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

A Phase 3 interventional study of Budesonide granules 9 mg and Placebo granules in Incomplete Microscopic Colitis, sponsored by Dr. Falk Pharma GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.

02

Conditions studied

  • Incomplete Microscopic Colitis

Browse trials for

03

In context

Colitis, Microscopic

23 studies on the registry are indexed under Colitis, Microscopic; 6 are open to participants now.

This study's enrollment of 44 is close to the median of 47 across 14 interventional studies indexed under Colitis, Microscopic.

Browse Colitis, Microscopic studies →

Lead sponsor

Dr. Falk Pharma GmbH is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • established diagnosis of incomplete microscopic colitis (MCi)
  • History of chronic non-bloody, watery diarrhoea
  • Clinically active disease

Exclusion criteria

Exclusion Criteria:

  • Other significant abnormalities in colonoscopy
  • Infectious cause of diarrhoea
  • Clinical suspicion of drug-induced diarrhoea
  • Prior and present MC
  • History of bowel resection
  • Radiation therapy of the abdominal or pelvic region
  • Positive antibody titres for celiac disease
  • Untreated active thyroid dysfunction
  • Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing
  • Abnormal hepatic function
  • Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured
  • History of colorectal cancer
  • History of cancer (other than colorectal) in the last 5 years
  • Therapy with immunomodulators/budesonide or other /antibiotics/anti-diarrhoeal drugs
  • Current or intended pregnancy or breast-feeding
  • Doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    A

    Budesonide granules 9 mg

    Drug: Budesonide granules 9 mg

  • Placebo comparator
    B

    Placebo granules

    Drug: Placebo granules

Interventions

  • DrugBudesonide granules 9 mg

    per day

  • DrugPlacebo granules

    per day

06

What researchers measure

Primary outcomes

  1. Rate of clinical remission

    Time frame: 8 weeks

Secondary outcomes

  1. Rate of clinical remission

    Time frame: 2 weeks

  2. Rate of clinical remission

    Time frame: 6 weeks

  3. Time to remission

    Time frame: 8 weeks

  4. Number of formed/soft/watery stools per week

    Time frame: 8 weeks

  5. Number of days with abdominal pain

    Time frame: 8 weeks

  6. Number of days with urgency

    Time frame: 8 weeks

  7. Rate of histological remission

    Time frame: 8 weeks

  8. Physician's global assessment at final visit

    Time frame: 8 weeks

  9. Quality of life

    Time frame: 8 weeks

07

Study locations

2 sites
  • Centre for Digestive Diseases
    Hamburg, 20249, Germany
  • University Hospital of Linköping, Dept. of Gastroenterology and Hepatology
    Linköping, 58185, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Feb 2020 and a completion of Feb 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2014
First posted
May 20, 2014
Start
May 2014
Primary completionActual
Feb 2020
CompletionActual
Feb 2020
Last update
Jul 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02142634
Responsible party
Sponsor
First posted
May 20, 2014
Start date
May 2014
Primary completion
Feb 2020
Completion
Feb 2020
Last update
Jul 22, 2020

Study contacts

Andreas Münch, MD
principal investigator · University Hospital of Linköping, Dept. of Gastroenterology and Hepatology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion